Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA ACT HF-TIMI 68
2024-517612-29-00Phase 4Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Time to first occurrence of cardiovascular death or worsening heart failure (composite endpoint component 1), Time to first occurrence of cardiovascular death or worsening heart failure (composite endpoint component 2) and 1 more. Started Nov 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2024-517612-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517612-29-00.